BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sun Y, Tisdale RK, Kilduff TS. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. Front Neurol Neurosci 2021;45:22-37. [PMID: 34052813 DOI: 10.1159/000514963] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Albert PR. Influence of functional gene polymorphisms on human behaviour: the case of CCR5. J Psychiatry Neurosci 2021;46:E659-62. [PMID: 34916235 DOI: 10.1503/jpn.210197] [Reference Citation Analysis]
2 Alain C, Pascal N, Valérie G, Thierry V. Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target. Molecules 2021;26:4849. [PMID: 34443437 DOI: 10.3390/molecules26164849] [Reference Citation Analysis]
3 Chepke C, Jain R, Rosenberg R, Moline M, Yardley J, Pinner K, Kumar D, Perdomo C, Filippov G, Atkins N, Malhotra M. Improvement in fatigue and sleep measures with the dual orexin receptor antagonist lemborexant in adults with insomnia disorder. Postgraduate Medicine. [DOI: 10.1080/00325481.2022.2049553] [Reference Citation Analysis]
4 Tran S, Prober DA. Validation of Candidate Sleep Disorder Risk Genes Using Zebrafish. Front Mol Neurosci 2022;15:873520. [DOI: 10.3389/fnmol.2022.873520] [Reference Citation Analysis]
5 Jha MK. Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy from a Phase 2B Study of Seltorexant. Int J Neuropsychopharmacol 2021:pyab078. [PMID: 34791262 DOI: 10.1093/ijnp/pyab078] [Reference Citation Analysis]